Soubrié, Philippe

Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V 1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders

Griebel, G., Simiand, J., Serradeil-Le Gal, C., Wagnon, J., Pascal, M., Scatton, B., Maffrand, J.-P., & Soubrié, P. (2002) · Proceedings of the National Academy of Sciences

Neuropeptides and Animal PhysiologyNeuroendocrine regulation and behavior

Cited by 471

Nicotine-associated cues maintain nicotine-seeking behavior in rats several weeks after nicotine withdrawal: reversal by the cannabinoid (CB1) receptor antagonist, rimonabant (SR141716)

Cohen, C., Perrault, G., Griebel, G., & Soubrié, P. (2005) · Neuropsychopharmacology

Smoking Behavior and CessationCannabis and Cannabinoid Research

Cited by 251

Characterization of (2 S,4 R)-1-[5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1 H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrrolidine carboxamide (SSR149415), a Selective and Orally Active Vasopressin V1b Receptor Antagonist

Gal, C. S.-L., Wagnon, J., Simiand, J., Griebel, G., Lacour, C., Guillon, G., Barberis, C., Brossard, G., Soubrié, P., Nisato, D., et al. (2002) · The Journal of Pharmacology and Experimental Therapeutics

Neuroendocrine regulation and behaviorNeuropeptides and Animal Physiology

Cited by 211